Relation of severe COVID-19 to polypharmacy and prescribing of psychotropic drugs: the REACT-SCOT case-control study

BMC Medicine

Stuart J. McGurnaghan¹  Thomas M. Caparrotta¹  Rachael Wood²  Sharon Kennedy²  Jen Bishop³  Amanda Weir³  Alison Smith-Palmer³  Jim McMenamin³  Janet Murray³  David Goldberg³  Chris Robertson⁴  Helen M. Colhoun⁵  David McAllister⁶  Sharon Hutchinson⁷  Nazir Lone⁸  Bruce Guthrie⁸  Paul M. McKeigue⁹ 

[1] Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, EH4 2XUC, Edinburgh, Scotland;NHS Information Services Division (Public Health Scotland), Gyle Square, 1 South Gyle Crescent, EH12 9EB, Edinburgh, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;Department of Mathematics and Statistics, University of Strathclyde, 16 Richmond Street, G1 1XQ, Glasgow, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;Institute of Genetics and Molecular Medicine, College of Medicine and Veterinary Medicine, University of Edinburgh, Western General Hospital Campus, Crewe Road, EH4 2XUC, Edinburgh, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ, Glasgow, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland;Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, EH8 9AG, Edinburgh, Scotland;Usher Institute, College of Medicine and Veterinary Medicine, University of Edinburgh, Teviot Place, EH8 9AG, Edinburgh, Scotland;Public Health Scotland, Meridian Court, 5 Cadogan Street, G2 6QE, Glasgow, Scotland;

关键词: COVID-19;    Pharmacoepidemiology;    Antipsychotic agents;    Opioids;    Gabapentinoids;    Proton pump inhibitors;    Polypharmacy;    Overprescribing;   

DOI  :  10.1186/s12916-021-01907-8

来源: Springer

【 摘 要 】

BackgroundThe objective of this study was to investigate the relation of severe COVID-19 to prior drug prescribing.MethodsSevere cases were defined by entry to critical care or fatal outcome. For this matched case-control study (REACT-SCOT), all 4251 cases of severe COVID-19 in Scotland since the start of the epidemic were matched for age, sex and primary care practice to 36,738 controls from the population register. Records were linked to hospital discharges since June 2015 and dispensed prescriptions issued in primary care during the last 240 days.ResultsSevere COVID-19 was strongly associated with the number of non-cardiovascular drug classes dispensed. This association was strongest in those not resident in a care home, in whom the rate ratio (95% CI) associated with dispensing of 12 or more drug classes versus none was 10.8 (8.8, 13.3), and in those without any of the conditions designated as conferring increased risk of COVID-19. Of 17 drug classes postulated at the start of the epidemic to be “medications compromising COVID”, all were associated with increased risk of severe COVID-19 and these associations were present in those without any of the designated risk conditions. The fraction of cases in the population attributable to exposure to these drug classes was 38%. The largest effect was for antipsychotic agents: rate ratio 4.18 (3.42, 5.11). Other drug classes with large effects included proton pump inhibitors (rate ratio 2.20 (1.72, 2.83) for = 2 defined daily doses/day), opioids (3.66 (2.68, 5.01) for = 50 mg morphine equivalent/day) and gabapentinoids. These associations persisted after adjusting for covariates and were stronger with recent than with non-recent exposure.ConclusionsSevere COVID-19 is associated with polypharmacy and with drugs that cause sedation, respiratory depression, or dyskinesia; have anticholinergic effects; or affect the gastrointestinal system. These associations are not easily explained by co-morbidity. Measures to reduce the burden of mortality and morbidity from COVID-19 should include reinforcing existing guidance on reducing overprescribing of these drug classes and limiting inappropriate polypharmacy.RegistrationENCEPP number https://EUPAS35558

【 授权许可】

CC BY